A cheap plant compound taken in short high-dose bursts to clear worn-out cells that build up with age. The laboratory and animal case is strong; the human case is thin. Small controlled trials in cancer, stroke, and obesity lower blood markers of inflammation, but none measured worn-out cells. Large doses reliably upset the gut. Safety looks good so far. (Full Review)
| Marker | Target | Why |
|---|---|---|
| High-sensitivity C-reactive protein (hs-CRP) | < 0.5 mg/L | Primary target; the marker most consistently moved by fisetin in trials |
| Interleukin-6 (IL-6) | < 1.5 pg/mL | Upstream driver of C-reactive protein and a core senescence-associated secretory phenotype component |
| Tumour necrosis factor-alpha (TNF-α) | < 2.0 pg/mL | Second senescence-associated secretory phenotype component reduced by fisetin in controlled trials |
| Fasting insulin | 2–5 µIU/mL | Detects the metabolic effect seen in the controlled trials, earlier than glucose does |
| Fasting glucose | 75–85 mg/dL | Confirms the metabolic signal and flags additive low blood sugar if on diabetes medication |
| Haemoglobin A1c | < 5.4 % | Three-month average glucose; filters out day-to-day noise in fasting values |
| Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) | ALT < 20 U/L (women), < 25 U/L (men); AST similar | Liver safety; fisetin is hepatically handled and competes for conjugation pathways |
| Estimated glomerular filtration rate (eGFR) | > 90 mL/min/1.73 m² | Kidney safety; fisetin conjugates are renally cleared |
| Complete blood count with platelets | Platelets 200–350 ×10⁹/L | Bleeding risk surveillance, relevant given flavonol antiplatelet activity |
| International normalised ratio (INR) | Within the individual's prescribed target | Detects the warfarin interaction, the fisetin interaction with the most serious potential consequence |
| Blood pressure, seated and standing | < 120/80 mmHg seated, with < 20 mmHg systolic drop on standing | Detects additive blood-pressure lowering reported with fisetin |
| Lipid panel with apolipoprotein B | Apolipoprotein B < 80 mg/dL | Captures the lipid improvements seen when fisetin was combined with training |
Cadence: Baseline within four weeks before the first dose. On a continuous low-dose regimen, inflammatory and metabolic markers at 8 and 12 weeks, then every 6 months. On an intermittent regimen, blood pressure on dosing days of the first two cycles, liver and kidney measures after cycle 3, the full inflammatory and metabolic panel after cycle 6, then every 6 to 12 months. Any change in prescription medication resets this schedule.